TECFIDERA (dimethyl fumarate) 120mg and 240mg delayed-release caps by Biogen Idec Biogen presented new data at ECTRIMS showing that Tecfidera (dimethyl fumarate) significantly reduced multiple ...
(Reuters) - A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish ...
Defending its blockbuster multiple sclerosis drug Tecfidera from generics hasn't been easy for Biogen lately, and the painful trend continued this week with a court ruling that clears the way for more ...
Biogen’s contingency plan to keep Tecfidera generics at bay has fallen flat. After a U.S. appeals court in November declined to resurrect a key patent on Biogen’s multiple sclerosis (MS) blockbuster ...
Tecfidera (dimethyl fumarate) is a prescription drug that’s used to treat certain types of multiple sclerosis. The drug comes as a delayed-release oral capsule. Tecfidera may not be safe to take while ...
WASHINGTONThe Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease. The twice-a-day ...
Warehoused patients, months of Wall Street hype, and positive clinical data all added to the anticipation around Biogen Idec’s Tecfidera MS drug. Months following launch, this Cinderella story—of a ...
This is the first FDA-approved therapeutically equivalent, substitutable generic of Tecfidera. Mylan announced the launch of Dimethyl Fumarate Delayed-Release Capsules, the first Food and Drug ...
The European Commission has pulled marketing authorisations for generic versions of Biogen’s oral multiple sclerosis therapy Tecfidera, after concluding that the brand qualifies for additional ...
Biogen CFO Paul Clancy told investors that a recently launched DTC campaign for multiple-sclerosis drug Tecfidera is showing “positive leading indicators,” including increased hits to the drug’s ...
The approval of Biogen Idec’s MS therapy Tecfidera follows months of breathless Wall Street hype, and it looks like doctors are psyched for the drug, too. In a MedLIVE PULSE survey conducted by ...
Biogen's (BIIB) Tecfidera was one of 2013's best new launches. Opening act Biogen's C-suite is likely smiling at its 2013 performance. Tecfidera blunts a lot of the risk tied to slowing sales for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback